BFM
ORKA

Boothbay Fund Management’s Oruka Therapeutics ORKA Stock Holding History

Boothbay Fund Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,481
Closed -$3.31M – 2712
2026
Q1 		$3.31M Buy
+67,481
New +$2.35M 0.04% 436
2025
Q3 		– Sell
-19,003
Closed -$213K – 2239
2025
Q2 		$213K Sell
19,003
-34,612
-65% -$361K ﹤0.01% 1225
2025
Q1 		$550K Buy
+53,615
New +$669K 0.01% 822

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Boothbay Fund Management's ORKA Position: Q2 2026 in Review

Boothbay Fund Management sold out of Oruka Therapeutics (ORKA) in Q2 2026, closing a stake of 67,481 shares — an estimated $3.31M sold.

Boothbay Fund Management first reported a position in ORKA in Q1 2025 and held it in 3 quarters. The position peaked at $3.31M in Q1 2026. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Boothbay Fund Management reported no remaining Oruka Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 67,481 Oruka Therapeutics shares in Q2 2026, an estimated $3.31M.
  • Boothbay Fund Management first reported a position in Oruka Therapeutics in Q1 2025 and held it in 3 quarters.
  • Boothbay Fund Management's Oruka Therapeutics position peaked at $3.31M in Q1 2026.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.